Kamalam Unninayar
CIK 1720065 · Chief Financial Officer · last filed 2019-04-02
Kamalam Unninayar is a Chief Financial Officer who has filed 5 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for HBIO, was dated Apr 2, 2019. Current disclosed insider exposure totals $333.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$333.6K
2
5
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HBIO | Chief Financial Officer | 54,861 | $6.08 | $333.6K | $0 | 3 | 2019-04-02 |
| TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Chief Financial Officer | — | — | — | $0 | 2 | 2018-01-19 |
Recent Filings
5 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-04-02 | HBIO | Grant (A) | +56,992 | $0 | EDGAR |
| 2019-01-03 | HBIO | Tax (F) | −1,603 | -$5.1K | EDGAR |
| 2018-11-27 | HBIO | Grant (A) | +18,469 | $0 | EDGAR |
| 2018-01-19 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-11-15 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Grant (A) | — | $0 | EDGAR |